Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2010
03/16/2010US7678787 Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
03/16/2010US7678786 Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol
03/16/2010US7678785 Fungicides; (E)-N-[2-((S)-3-Aminopyrrolidin-1-yl)-2-oxo-ethyl]-3-phenyl-N-(3'-trifluoromethoxy-biphenyl-4-yl)-acrylamide; inhibitors of beta -1,3-glucan synthase; readily synthesised by standard chemistry, and have more drug-like properties that are compatible with oral bioavailability
03/16/2010US7678784 4-amino-23,26-dichloro-13-oxa-3,5,18,21-tetraazatricyclo[20.2.2.29,12]octacosa-1(24),4,9,11,15,22,25,27-octaene-6,8,20-trione 8-(O-ethyloxime); beta -amyloid production blocking agent; neurodegenerative diseases, cognition activator; Alzheimer's disease, Down syndrome
03/16/2010US7678783 Inhibits the activity of beta -secretase or BACE, thus preventing the formation of insoluble A beta and arresting the production of A beta
03/16/2010US7678782 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
03/16/2010US7678781 11-phosphorous steroid derivatives useful as progesterone receptor modulators
03/16/2010US7678779 Methods for the administration of amifostine and related compounds
03/16/2010US7678778 Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
03/16/2010US7678777 increase a person immunity by oral administering a mixture including a dextran, promoting the cell growth and colonizing in the intestine of a subject without supplying L. casei subsp. casei at all times
03/16/2010US7678776 Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof
03/16/2010US7678775 ILK inhibitors for the treatment of renal disease
03/16/2010US7678774 Treating severe acute respiratory syndrome
03/16/2010US7678773 Salts of avermectins substituted in the 4″-position and having pesticidal properties
03/16/2010US7678772 Plant extracts; atherosclerosis, coronary heart disease, cataracts, dementia, Alzheimer's disease, melanomas, burns, diabetes, cancer, neurodegenerative disorders; cognition activators; wrinkle and aging resistance; free radical scavengers; solvent extraction, neutralization, purification aloe
03/16/2010US7678771 comprising L-lysine-d-amphetamine or salts; for treating attention deficit hyperactivity disorder
03/16/2010US7678770 Abuse-resistant amphetamine prodrugs
03/16/2010US7678764 Protein formulations for use at elevated temperatures
03/16/2010US7678760 Inhibitors of Memapsin 2 and use thereof
03/16/2010US7678558 Method for overexpression of zwitterionic polysaccharides
03/16/2010US7678549 Polyphenol inhibition of nucleoside diphosphate kinase-B activity and cancer metastasis
03/16/2010US7678395 stimulating the growth of hair in an area on the surface of a hair-bearing subject by administering to said area a composition that comprises isolated and purified isoginkgetin
03/16/2010US7678391 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
03/16/2010US7678384 Insecticides, miticides, anthelmintics, nematocides for use on domestic animals, transgenic plants; 1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-[methyl(vinyl)amino]-4-[(trifluoromethyl)sulfonyl]-1H-pyrazole-3-carbonitrile for example
03/16/2010US7678383 Aminoacetonitrile compounds for controlling endoparasites
03/16/2010US7678380 Cosmetic treatment method for fighting against skin ageing effects
03/16/2010US7678369 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents
03/16/2010US7678366 for high penetration into fingernails and toenails; contains humectant for trapping water and liquid nail lacquer containing film forming agent
03/16/2010US7678146 May be used for medical indications, such as an implantable or injectable endoprostheses for mammoplastic reconstruction, implantable or injectable endoprostheses for treating (reflux) oesophagitis, and for body contouring of various body parts
03/16/2010CA2639525A1 Topical composition for the protection and/or treatment of radiation related skin damages
03/16/2010CA2576734C Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
03/16/2010CA2554169C Myocardial perfusion imaging using adenosine receptor agonists
03/16/2010CA2526586C The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
03/16/2010CA2512683C Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
03/16/2010CA2510519C Condensed furan compounds
03/16/2010CA2500492C Aryl sulfonamides
03/16/2010CA2492467C Injectable depot formulation comprising crystals of iloperidone
03/16/2010CA2467695C Isomaltooligosaccharides from leuconostoc as neutraceuticals
03/16/2010CA2438646C Pyrimidine derivatives for inhibition of cell-proliferation
03/16/2010CA2437718C Carboline derivatives
03/16/2010CA2432006C Pharmaceutical preparation with retarding active ingredient release, method for its production and its use
03/16/2010CA2431521C Steroid hormone products and methods for preparing them
03/16/2010CA2424968C Solution for peritoneal dialysis
03/16/2010CA2415378C Oral pharmaceutical composition with controlled release and prolonged absorption
03/16/2010CA2396965C Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
03/16/2010CA2395121C Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method
03/16/2010CA2390590C Adenosine receptor antagonists and methods of making and using the same
03/16/2010CA2390047C Valnemulin formulation
03/16/2010CA2386980C Benzodiazepine derivatives for use in acute or chronic neurological disorders
03/16/2010CA2372575C Bradykinin receptor antagonists
03/16/2010CA2368617C Hydrogel-forming system with hydrophobic and hydrophilic components
03/16/2010CA2358420C New compounds for the treatment of cancer
03/16/2010CA2336846C Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric g protein
03/16/2010CA2329881C Compounds with growth hormone releasing properties
03/16/2010CA2314286C Anthelmintic compositions
03/16/2010CA2302838C Modulation of the sphingosine kinase signalling pathway
03/16/2010CA2274108C 2-cyclopenten-1-one and its derivatives as inhibitors of the nf-kb factor
03/16/2010CA2191577C Method for treating and preventing atherosclerosis
03/16/2010CA2160693C Oral drug delivery compositions and methods
03/16/2010CA2087817C 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
03/11/2010WO2010028338A2 Novel compounds as cannabinoid receptor ligands
03/11/2010WO2010028290A1 Chewable sustained release formulations
03/11/2010WO2010028281A1 Pharmaceutical composition of a radioiodinated benzamide derivative and methods of making the same
03/11/2010WO2010028259A2 9-aminonoscapine and its use in treating cancers, including drug- resistant cancers
03/11/2010WO2010028257A1 Sustained release formulations using non-aqueous carriers
03/11/2010WO2010028254A2 Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
03/11/2010WO2010028213A2 N-sulfonamido polycyclic pyrazolyl compounds
03/11/2010WO2010028211A1 Health care
03/11/2010WO2010028207A2 Method of treatment of attention deficit/hyperactivity disorder (adhd)
03/11/2010WO2010028193A1 Compounds including pimelic acid derivatives as hdac inhibitors
03/11/2010WO2010028192A1 Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
03/11/2010WO2010028190A2 Compounds, compositions and methods of using same for modulating uric acid levels
03/11/2010WO2010028189A2 Compounds, compositions and methods of using same for modulating uric acid levels
03/11/2010WO2010028187A2 Methods and compositions for the treatment of cancer
03/11/2010WO2010028179A1 Heterocyclic compounds as gata modulators
03/11/2010WO2010028175A1 Modulators of aldehyde dehydrogenase activity and methods of use thereof
03/11/2010WO2010028174A1 Novel biccyclic compounds as gata modulators
03/11/2010WO2010028173A2 Method of treating atrial fibrillation
03/11/2010WO2010028134A2 Treatment of neurological disorders using huperzine
03/11/2010WO2010028133A1 Imaging neuroleptic compounds
03/11/2010WO2010028132A2 Novel choline cocrystal of epalrestat
03/11/2010WO2010028130A2 Antidepressant compounds
03/11/2010WO2010028116A1 Macrocyclics pyrimidines as aurora kinase inhibitors
03/11/2010WO2010028108A2 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor
03/11/2010WO2010028101A1 Method for making cetirizine tablets
03/11/2010WO2010028093A2 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
03/11/2010WO2010028088A2 Sulfur-linked compounds for treating opthalmic diseases and disorders
03/11/2010WO2010028067A1 Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
03/11/2010WO2010028058A1 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
03/11/2010WO2010028051A2 Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
03/11/2010WO2010028033A1 Amides of diazabicyclooctanes and uses thereof
03/11/2010WO2010028015A2 2-oxo-1,2-dihydro-quinoline modulators of immune function
03/11/2010WO2010028011A1 Amides of diazabicyclononanes and uses thereof
03/11/2010WO2010027996A1 Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
03/11/2010WO2010027927A1 Monocyclic amide cgrp receptor antagonists
03/11/2010WO2010027875A2 Compounds that modulate intracellular calcium
03/11/2010WO2010027848A2 Forms of lapatinib compounds and processes for the preparation thereof
03/11/2010WO2010027838A1 Mir 204, mir 211, their anti-mirs, and therapeutic uses of same
03/11/2010WO2010027832A1 Method for reducing scarring during wound healing using antisense compounds directed to ctgf
03/11/2010WO2010027783A1 Methods and compositions for the treatment and prevention of citrus greening disease
1 ... 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 ... 7860